Phase 3
N=69
Empowering Patients to Better Manage Diabetes Through Self-Care
Type I or Type II Diabetes (Excludes Gestational Diabetes)
Bottom Line
View on ClinicalTrials.gov: NCT00254501 ↗Enrolled (actual)
69
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcome: Primary: Change in Hemoglobin A-1C From Baseline — -0.16; -0.50 percentage of glycolsylated hemoglobin — p=0.0757
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Pharmacist Counseling (Behavioral); Educational materials (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Oregon State University
- Primary completion
- Jun 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Hemoglobin A-1C From Baseline |
-0.16; -0.50 | 0.0757 |
| SECONDARY Changes From Baseline in LDL, HDL, Total Cholesterol, Triglycerides |
0.1; -3.9; -3.6; -6.3; -5.1; -11.6 | 0.44 |
| SECONDARY Changes in Economic Outcomes (Total Cost of Care, Cost of Diabetes Medications, Cost of Diabetes Supplies) From Baseline to 12 Months |
-89; 1612; 516; 450; 237; 191 | .3856 |
| SECONDARY Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months |
0.29; 0.17; 0.25; -0.65; -0.14; 0.54 | 0.785 |
Summary
This study will look at the impact of health insurance benefits on self management of diabetes for people with this condition. Studies have shown that when people with diabetes manage their disease better, they stay healthier. Our goal in this study is to help those with diabetes better manage their disease (self-care). We will compare two types of health insurance benefits in this study. We want to see if one set of benefits improves self-care more than the other one.
Eligibility Criteria
Inclusion Criteria
- diabetes (Type I or Type II)
- enrolled in health plan with participating employer
- age 18 or older
- willing and able to provide informed consent
Exclusion Criteria
- gestational diabetes
Data sourced from ClinicalTrials.gov (NCT00254501). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.